Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,701–1,800 of 2,162
Cytokine Release Syndrome: An Overview on its Features and Management
Shreshtha, S., Kumar, P., Sharma, P. A., & Sharma, R. (2019) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.13.1.14 · Cited by 2
Preclinical Development of Monoclonal Antibodies
Meyer-Tamaki, K. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00023-2 · Cited by 1
A new mouse model for human immune system-related translational studies
Żołędziewska, M. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102213 · Cited by 1
Pharmacology‐Guided Rule‐Based Adaptive Dose Escalation in First‐in‐Human Studies
van Hoogdalem, E., van Iersel, M. T., Winter, E., Constant, J., & Kappler, M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2101 · Cited by 1
“, 66% and 100% of participants receiving active treatment.(11-14) At these high rates, small sample sizes suffice to observe at least one DLE with a sufficiently high probability; for example, a sample size of just one active-dosed participant has, intuitively, an 80% probability of observing a DLE with a rate of 80%,…”
BackgroundEl-Hak, H. N. G. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.28.004698 · Cited by 1
“Suntharalingam, Perry [21] found in six healthy volunteer men were left in intensive care with multiple organ failure most notably early acute lung injury and marked lymphopenia after 90 minutes of received a new kind of drug as a result of an out of control cytokine immune response during a preclinical trial.”
BackgroundLondon, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0001 · Cited by 2
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0005 · Cited by 1
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K. D., & Shenton, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100601-6.02008-1 · Cited by 1
Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1586-3_2 · Cited by 1
Focosi, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69884-x · Cited by 1
From innovative thinking to pharmaceutical industry implementation: Some success stories
Walley, R. J., & Brayshaw, N. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2222 · Cited by 1
Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy
Greenbaum, U., Ramdial, J., Afrough, A., Alsfeld, L. C., Ghanem, S., Daher, M., Olson, A. L., Kebriaei, P., Strati, P., Steiner, R. E., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00035-8 · Cited by 1
Roškar, Z., Dreisinger, M., Tič, P., Homšak, E., Bevc, S., & Goropevšek, A. (2023) · Biosensors · doi:10.3390/bios13050539 · Cited by 2
“Recent trials emphasized the importance of directly assessing the human immune response, and that not all of what we learn, for example, in rodents can be directly translated to humans [20,21].”
BackgroundSpecies Selection for Pharmaceutical Toxicity Studies
Harvey, W. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_133-1 · Cited by 2
Respiratory Delivery of Bacteriophages for the Treatment of Lung Infections
Byun, A. S., Chan, H., & Kwok, P. C. L. (2023) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-47567-2_8 · Cited by 2
Role of the SARS-CoV-2 Virus in Brain Cells
Azargoonjahromi, A. (2024) · Viral Immunology · doi:10.1089/vim.2023.0116 · Cited by 2
“…the administration of TGN1412, a monoclonal antibody stimulating T cells, a cytokine storm occurred, resulting in symptoms, including headache, myalgias, erythema, vasodilation, and hypotension, with elevated levels of TNF-a , IFN-g , IL-1 b , IL-6, IL-8, and IL-10 (Suntharalingam et al., 2006).”
Colagiovanni, D. B., & Peraza, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00020-7 · Cited by 1
Johnson, V. J., Corsini, E., & Germolec, D. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00035-8 · Cited by 1
Arndt, T., Keresztes, M., Blanck, O., et al. (2024) · Toxicologic Pathology · doi:10.1177/01926233241245108 · Cited by 1
Modern principles of predicting the course of pneumonia in COVID-19
Aliev, A. A., Антонян, В. В., Абдурагимович, К. Э., Ostroverkhov, O. P., & Babaeva, A. R. (2024) · ASTRAKHAN MEDICAL JOURNAL · doi:10.17021/1992-6499-2024-1-6-16 · Cited by 1
Wu, Y., Liang, X., Sun, Y., Ning, J., Dai, Y., Jin, S., Xu, Y., Chen, S., & Pan, L. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200827 · Cited by 1
“39 To enhance safety in fi rst-in-human clinical testing using monoclonal antibodies, several measures have been proposed.”
Sentinel Dosing—Time for a Risk‐Based Approach?
Bonate, P. L., Rogge, M. C., Gries, J., Prokopienko, A. J., & Pai, S. M. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6167 · Cited by 1
The United States Federal Drug Administration (FDA) and Clinical Research
Glasser, S. P., Ashton, C. M., & Wray, N. P. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8486-7_6 · Cited by 1
Goetz, K., Sun, Y., Féchir, K., Kretzschmar, E., & Buettel, I. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9524-6_25 · Cited by 1
Multiple Sklerose und andere autoimmune ZNS-Erkrankungen
Kroner, A., Kleinschnitz, C., Stadelmann, C., Raab, P., Stangel, M., Trebst, C., Voß, E. V., & Cordes, A.-L. (2011) · Springer eBooks · doi:10.1007/978-3-642-20477-7_1 · Cited by 4
Hacia un tratamiento no empírico de la artritis reumatoide basado en su patogenia molecular
Moreno, J. G., Vázquez-Ortíz, G., López-Blanco, J. A., López-Romero, R., & Medina, F. (2008) · Reumatología Clínica · doi:10.1016/s1699-258x(08)71791-1 · Cited by 2
Du, X., Nagata, S., Ise, T., et al. (2007) · Molecular Cancer Therapeutics · Cited by 1
Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies
Ishii‐Watabe, A., Tada, M., Suzuki, T., et al. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00007-3 · Cited by 1
Multiple organ dysfunction syndrome
Figgis, P. A., & Bihari, D. J. (2009) · Elsevier eBooks · doi:10.1016/b978-0-7020-3096-3.00013-0 · Cited by 1
Human IgG Glycosylation in Inflammation and Inflammatory Disease
Jefferis, R. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00099-4 · Cited by 4
Novel Generation of Antibody-Based Therapeutics
Brezski, R. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00006-7 · Cited by 1
Characteristics and Dissemination of Phase 1 Trials Approved by a UK Regional Office in 2012
Odutayo, A., Copsey, B. J., Dutton, S., Cook, J. A., Hopewell, S., & Altman, D. G. (2017) · JAMA · doi:10.1001/jama.2017.1471 · Cited by 1
Novel Drugs in Kidney Transplantation
Chandran, S., & Vincenti, F. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00021-7 · Cited by 1
Cytokines: Role in Homeostasis and Disease States
Prell, R. A., & Tarrant, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64237-x · Cited by 2
Kleine Moleküle, ganz groß: niedermolekulare immunonkologische Kombinationstherapien
Huck, B. R., Kötzner, L., & Urbahns, K. (2018) · Angewandte Chemie · doi:10.1002/ange.201707816 · Cited by 2
Burt, T., & Combes, R. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813697-3.00026-3 · Cited by 1
Anderson, D. J., Lo, D. J., Leopardi, F., Song, M., Strobert, E. A., Jenkins, J. B., Larsen, C. P., & Kirk, A. D. (2019) · Clinical Transplantation · doi:10.1111/ctr.13568 · Cited by 1
Expanding the Clinical Cytometry Toolbox—Receptor Occupancy by Mass Cytometry
Huse, K. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23784 · Cited by 1
“However, despite using doses 500 times lower than the dose found safe in animal models, the human volunteers involved in the trial suffered severe cytokine release syndrome and multiple organ failure after receiving the drug (2).”
BackgroundReceptor occupation in the fjords
Gavasso, S., Bringeland, G. H., & Tárnok, A. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23910 · Cited by 1
“In 2006, the clinical Phase I trial in anti-CD28 therapy in healthy human individuals taught the field of biopharmaceuticals a tough lesson: Unexpected low receptor levels in humans compared to monkeys dramatically increased RO, causing a cytokine storm in human subjects that was never observed in animal models (3).”
BackgroundIn Vitro Assays for Assessing Potential Adverse Effects of Cancer Immunotherapeutics
Li, J., Mitra, M. S., & Rao, G. K. (2020) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-0171-6_12 · Cited by 1
Precision Medicine: The Function of Receptor Occupancy in Drug Development
Flye, L. A., Gonneau, C., Selliah, N., et al. (2020) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-0171-6_11 · Cited by 1
Trahtemberg, U., Darawshe, F., Elazary, R., Ginsburg, I., Beil, M., van Heerden, P. V., & Sviri, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15309 · Cited by 2
Garzone, P. D. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385471-1.00034-9 · Cited by 1
Approaches to the Induction of Tolerance
Wood, K. J. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4096-3.00023-4 · Cited by 1
Harnessing Newton’s third-law paradigm to treat autoimmune diseases and chronic inflammations
Nguyen, T. G. (2020) · Inflammation Research · doi:10.1007/s00011-020-01374-6 · Cited by 1
Therapeutic antibody development—Remington chapter
Geist, B. J., Zheng, S., & Xu, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00024-6 · Cited by 1
Takimoto, C. H. M., Wick, M. J., Agoram, B. M., & Jin, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00031-8 · Cited by 1
17α-Hydroxyprogesterone Caproate Inhibits Cytokine Production via Suppression of NF-κB Activation
Hu, T., Tang, C., Stern, S., Yang, L., & Du, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831315 · Cited by 1
“This is consistent with the clinical observations which showed elevated circulating levels of IL-10 in patients with CRS associated with COVID-19, TGN1412, and CAT-T cell therapy (Suntharalingam et al., 2006; Morris et al., 2021; Yang et al., 2021).”
ResultPugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0001 · Cited by 1
Diversity of CD28null T Cells in the Elderly: A Glimpse in a Biological Adaptation of Aging
Griffin, P. C., Michel, J. J., & Vallejo, A. N. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_87 · Cited by 1
Diagnostics and Personalized Medicine
Zanders, E. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-57814-5_14 · Cited by 1
Biomolecules Versus Smaller Chemicals in Toxicology: ICH, EU, and US Recommendations
Ruthsatz, M., Chiavaroli, C., Cassar, M. A., & Voisin, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-57499-4_57 · Cited by 1
Gülşen, A., Wedi, B., & Jappe, U. (2020) · Allergo Journal · doi:10.1007/s15007-020-2567-5 · Cited by 1
Recent Developments in the Immunotherapeutic Approaches for Cancer Treatment
Bharadwaj, S., Kirtipal, N., & Sobti, R. C. (2022) · Springer eBooks · doi:10.1007/978-981-16-8845-4_21 · Cited by 3
Ethical Issues in Cardiovascular Behavioral Medicine Research
Katzel, L. I., & Shamoo, A. E. (2022) · Springer eBooks · doi:10.1007/978-0-387-85960-6_63 · Cited by 1
Inflammation and Organ Failure
Pruett, S. B., Tan, W., Sebastian, T., & Liu, D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00617-5 · Cited by 1
Acharya, S., & Fathman, C. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-77909-6_11 · Cited by 1
“However, many therapies that are successful in animal models [6] are not effective in treating the human disease, as seen in studies on MS [7], adverse outcome of treatment with Interferon- [8], development of progressive multifocal leukoencepahlopathy in recipients of an adhesion molecule blocker in MS [9,10], and ma…”
BackgroundLarge Animal Models of Transplantation
Anderson, D. J., Martin, B. M., Kirk, A. D., & Sachs, D. H. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch15 · Cited by 1
Application of Flow Cytometry in Drug Development
Narayanan, P. K., Capocasale, R. J., Li, N., & Bugelski, P. J. (2008) · Wiley eBooks · doi:10.1002/9780470386385.ch11 · Cited by 1
Arzneimitteltestung am Menschen
Otte, A. (2007) · Der Internist · doi:10.1007/s00108-007-1798-9 · Cited by 1
IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Brennan, F. R. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch36 · Cited by 1
Chen, J., & Dongré, A. R. (2012) · Wiley eBooks · doi:10.1002/9781118180778.ch5 · Cited by 1
Toxicology and Adverse Drug Reactions
Snodin, D. J., & Suitters, A. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch3 · Cited by 1
Toda, T., & Nakamura, K. (2014) · Wiley eBooks · doi:10.1002/9783527676965.ch7 · Cited by 1
Characterization of Recombinant Proteins
Giese, C., von Horsten, H., & Zietze, S. (2012) · Pharmaceutical biotechnology · doi:10.1002/9783527632909.ch9 · Cited by 1
Combination and Adjuvant Therapies to Facilitate the Efficacy of Costimulatory Blockade
Srinivasan, S. K., Triemer, H. L., & Kirk, A. D. (2010) · Wiley eBooks · doi:10.1002/9781444355628.ch28 · Cited by 1
Clinical and pathophysiological aspects of sepsis
Linnér, A. (2014) · Figshare · Cited by 1
Tolérance immunitaire vis-à-vis d’auto-antigènes du système nerveux : implications thérapeutiques
Liblau, R., & Cassan, C. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)92155-4 · Cited by 1
Antibody drugs: the present status and perspectives
Kawanishi, T. (2008) · Folia Pharmacologica Japonica · doi:10.1254/fpj.131.102 · Cited by 1
Robertson, M. (2009) · Journal of Biology · doi:10.1186/jbiol175 · Cited by 1
“The trial of TGN1412 in 2006 is a dramatic case in point [7].”
BackgroundMaking antibodies from scratch
Love, J. C. (2010) · Nature Biotechnology · doi:10.1038/nbt1110-1176 · Cited by 1
Naissance et développement de l’immunothérapie ciblée : La révolution des biomédicaments
Sibilia, J. (2007) · Revue du Rhumatisme · doi:10.1016/s1169-8330(07)80611-9 · Cited by 1
Réactions d’hypersensibilité dues aux agents modifiant la réponse biologique (biologicals)
Bircher, A. J., & Scherer, K. (2009) · Revue française d'allergologie · doi:10.1016/j.reval.2009.01.025 · Cited by 1
The evolution of clinical immunology and allergy in Australia
Basten, A. (2007) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100138 · Cited by 1
New drugs: Kids come first; Con: First adults, then children
Murphy, S. M. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20179 · Cited by 1
Cell-based therapies: careful safety assessment for minimization of risk
Comoli, P. (2010) · Cytotherapy · doi:10.3109/14653249.2010.517392 · Cited by 1
Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodies
Chamberlain, P. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.017 · Cited by 1
MEMBERSHIP OF THE WORKING PARTY
Wilkinson, D. J., Président, V., Aitken, H., McNicol, R., Fitzwilliams, B., Jackson, I., President, M. H., Wallace, P. A., Birks, R. J. S., Whitaker, D., et al. (2010) · Cited by 1
Co-stimulatory pathways in the therapy of rheumatoid arthritis
Ruderman, E., & Pope, R. M. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8238-4_2 · Cited by 1
“antibody was administered to human volunteers, cytokine storm was induced resulting from the rapid induction of cytokines [ 47 ].”
BackgroundMethodZeng, D., & Strober, S. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch12 · Cited by 1
Overview Of Antibody- Based Therapeutics Present And Future Promise
Grewal, I. S. (2009) · CRC Press eBooks · doi:10.1201/9781420063219-6 · Cited by 1
Aspects of the mode of action of bispecific T cell engager (BiTE) antibodies
Hauff, C. (2009) · Online Publication Service of Würzburg University (Würzburg University) · Cited by 2
Mirenda, V., Jarmin, S. J., David, R., et al. (2006) · Cited by 1
Bakács, T., Moss, R. W., Szász, A. M., & Anderson, C. C. (2018) · Preprints.org · doi:10.20944/preprints201811.0609.v1 · Cited by 1
“critically re-considered the very same published evidence and suggested an alternative interpretation of the widespread irAEs by comparing the outcomes of the ipilimumab trials and the phase I clinical trial of a humanized ‘superagonist’ anti-CD28 mAb (TGN1412), which ended up in a catastrophe [23].”
ResultResearch and innovative treatment
Lynch, J., Terry, L. M., Battersby, S., et al. (2010) · CRC Press eBooks · doi:10.1201/b21792-14 · Cited by 1
Lloyd, P. M., & Sims, J. (2013) · doi:10.1002/9781118532331.ch6 · Cited by 1
Arzneimitteltestung am Menschen: Die Risiken im Licht der Katastrophe von London
Otte, A. (2007) · Der Internist · Cited by 1
Banaszek, A. (2013) · Online Publication Service of Würzburg University (Würzburg University) · Cited by 1
T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Brennan, F. R. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch32 · Cited by 1
Preclinical Evaluation of Immunotoxicity
Henson, K. L. (2022) · Schalm's Veterinary Hematology · doi:10.1002/9781119500537.ch14 · Cited by 1
Humanized Mouse Models for Cancer Immunotherapy: A Focus on Human PBMC and HSPC Reconstitution
Li, Z. Y., Yang, X. J., & Song, X. (2022) · Wiley eBooks · doi:10.1002/9781119535331.ch7 · Cited by 1
T-Cell Costimulatory Molecules
Sun, Q., & Li, X. C. (2022) · Springer eBooks · doi:10.1007/978-981-19-6111-3_2 · Cited by 1
Woolf, R., & Smith, C. H. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook014 · Cited by 1
Thisted, T., Smith, F. D., Jiang, Z.-G., Biesová, Z., Onumajuru, A. M., Kleschenko, Y., Malhotra, K., Saxena, V., Mukherjee, A., & van der Horst, E. H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.07.647657 · Cited by 1
“…antibodies through receptor agonism without associated toxicity is particularly prudent in the context of CD28, where superagonism (i.e. full T-cell activation in the absence of TCR ligation) can lead to severe life-threatening toxicity in the form of cytokine release syndrome (CRS; (7)).”
Upadhyay, S., Nada, H., Cho, S. W., & Gabr, M. T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680836 · Cited by 1
“The catastrophic cytokine storm observed with the CD28 superagonist TGN1412 highlighted the risks of indiscriminate activation (Suntharalingam et al., 2006), while subsequent development of antagonistic antibodies (e.g., FR104, lulizumab) and CTLA-4-Ig fusion proteins (abatacept, belatacept)…”
Niesner, U., Albrecht, I., & Radbruch, A. (2007) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2007_037
“Future studies will reveal the potential of this approach, although expectations have been dampened by the lack of success using a superagonistic anti-CD28 antibody ( Suntharalingam et al. 2006 ).”
BackgroundFuture clinical prospects for entry inhibitors
Heath, S. L., & Kilby, J. M. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7783-0_10
“phocytes [40]. At the other immunological extreme, a recent study involving normal volunteers taking a single test dose of an anti-CD28 mAb, designed to modulate T cell immunoactivation, resulted in dramatic and unexpected consequences, essentially a life-threatening cytokine storm and multi-organ failure [ 41 ].”
BackgroundWinstead, C. J. (2009) · University of Minnesota Digital Conservancy (University of Minnesota)
Chemotherapy and Novel Targeted Therapies
Ronghe, M., & Murphy, D. (2008) · Springer eBooks · doi:10.1007/978-3-540-29734-5_7
Das, A., Mondal, B., Bose, A., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.08.004
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.